MORE ZERO-MIGRAINE DAYS ARE POSSIBLE

Consider QULIPTA® as Your First-Line Preventive of Choice

Across 12 weeks, QULIPTA® 60 mg reduced attacks for both episodic and chronic migraine patients.¹

EM primary endpoint: Significant -4.2 monthly migraine day reduction from 7.8 baseline (n=222; P<0.001) vs -2.5 from 7.5 baseline for placebo (n=214)¹*

CM primary endpoint: Significant -6.9 monthly migraine day reduction from 19.2 baseline (n=256; P<0.001) vs -5.1 from 18.9 baseline for placebo (n=246)^1†

*Data from Phase 3 ADVANCE EM pivotal study.
^†Data from Phase 3 PROGRESS CM pivotal study.
^‡Specific to episodic migraine. Data from Phase 3 ADVANCE EM pivotal study.
^§Data pooled from Phase 2b/3 Dose Finding Study, Phase 3 ADVANCE EM pivotal study, and data from Phase 3 PROGRESS CM pivotal study.

NOW APPROVED FOR CHRONIC MIGRAINE

QULIPTA: A FIRST-LINE PREVENTIVE MIGRAINE TREATMENT OPTION^1,5 
MORE PATIENTS THAN EVER BEFORE HAVE
ZERO-STEP ACCESS TO QULIPTA^4¶#

SEE COVERAGE IN YOUR AREA

Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.

AHS=American Headache Society; CGRP=calcitonin gene-related peptide; CM=chronic migraine; EM=episodic migraine.

^¶Zero-step coverage means the patient does not need to try and fail a prior therapy.

^#Managed Markets Insight & Technology, LLC™, a trademark of MMIT. Data as of July 2025 and subject to change.

Episodic migraine study design (ADVANCE; Phase 2b/3 dose-finding study)

Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 4 to 14 migraine days per month. Patients in trials were 88% female, 80% White, 17% Black, and 12% Hispanic or Latino ethnicity, and the mean age at study entry was 41 years (range 18-74 years). The studies excluded patients with myocardial infarction, stroke, or transient ischemic attacks within 6 months prior to screening.^1,4

Chronic migraine study design (PROGRESS)

A randomized, double-blind, placebo-controlled, parallel-group study that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 15 or more migraine days per month. Patients in trials were 87% female, 60% White, 3% Black, 36% Asian, and 4% Hispanic or Latino ethnicity, and the mean age at study entry was 42 years (range 18-74 years). A subset of patients (11%) was allowed to use 1 concomitant migraine preventive medication. The study excluded patients with myocardial infarction, stroke, or transient ischemic attacks within 6 months prior to screening.^1,2

Open-label, long-term safety study design

A multicenter, randomized, open-label, 52-week long-term safety study to evaluate the safety and tolerability of QULIPTA 60 mg in participants who experienced 4 to 14 migraine days per month. Participants were randomized to either QULIPTA 60 mg once daily or oral standard-of-care migraine prevention medication. Efficacy variables for long-term efficacy evaluation were not classified as primary, secondary, or additional endpoints. Efficacy measures were only collected for the QULIPTA group. For the 521 participants in the QULIPTA group in the mITT population, mean age was 42.5 years (range 18 to 78 years), 88.3% were female, 76.8% were White, and 15.7% were of Hispanic or Latino ethnicity.^2,3

mITT=modified intention-to-treat.

READ REAL PATIENT STORIES

MORE ZERO-MIGRAINE DAYS ARE POSSIBLE

QULIPTA: A FIRST-LINE PREVENTIVE MIGRAINE TREATMENT OPTION1,5 MORE PATIENTS THAN EVER BEFORE HAVE ZERO-STEP ACCESS TO QULIPTA4¶#

QULIPTA: A FIRST-LINE PREVENTIVE MIGRAINE TREATMENT OPTION^1,5 
MORE PATIENTS THAN EVER BEFORE HAVE
ZERO-STEP ACCESS TO QULIPTA^4¶#